We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Savara
SVRA
$1.08B
| $11.1K | ﹤0.01% |
+3,604
| New | +$12.6K |
|
|
TRML
527
DELISTED
Tourmaline Bio
TRML
| $10.9K | ﹤0.01% |
+538
| New | +$13.5K |
|
528
NiSource
NI
$21.5B
| $10.9K | ﹤0.01% |
+296
| New | +$10.6K |
|
|
WSR
529
DELISTED
Whitestone REIT
WSR
| $10.9K | ﹤0.01% |
+767
| New | +$10.9K |
|
|
PPL
530
PPL Corp
PPL
$26.9B
| $10.8K | ﹤0.01% |
+334
| New | +$11K |
|
531
Altimmune
ALT
$568M
| $10.8K | ﹤0.01% |
+1,493
| New | +$11.4K |
|
532
DTE Energy
DTE
$29.9B
| $10.7K | ﹤0.01% |
+89
| New | +$11K |
|
533
CMS Energy
CMS
$23.3B
| $10.7K | ﹤0.01% |
+161
| New | +$11.1K |
|
|
DFTX
534
Definium Therapeutics
DFTX
$5.6B
| $10.7K | ﹤0.01% |
+1,540
| New | +$10.6K |
|
535
Evergy
EVRG
$19.4B
| $10.7K | ﹤0.01% |
+174
| New | +$10.8K |
|
536
Ameren
AEE
$30.4B
| $10.7K | ﹤0.01% |
+120
| New | +$10.7K |
|
537
EyePoint Inc
EYPT
$999M
| $10.7K | ﹤0.01% |
+1,433
| New | +$13.3K |
|
538
Xeris Biopharma Holdings
XERS
$1.45B
| $10.6K | ﹤0.01% |
+3,130
| New | +$10.1K |
|
|
ATXS
539
DELISTED
Astria Therapeutics
ATXS
| $10.6K | ﹤0.01% |
+1,185
| New | +$12.6K |
|
540
Pacific Biosciences
PACB
$435M
| $10.5K | ﹤0.01% |
+5,750
| New | +$11.2K |
|
541
CorMedix
CRMD
$564M
| $10.3K | ﹤0.01% |
+1,274
| New | +$12.7K |
|
|
VERV
542
DELISTED
Verve Therapeutics
VERV
| $10K | ﹤0.01% |
+1,778
| New | +$10K |
|
543
MeiraGTx Holdings
MGTX
$1.08B
| $9.99K | ﹤0.01% |
+1,641
| New | +$9.62K |
|
|
TERN
544
DELISTED
Terns Pharmaceuticals
TERN
| $9.88K | ﹤0.01% |
+1,783
| New | +$12.1K |
|
|
AUTL
545
Autolus Therapeutics
AUTL
$389M
| $9.85K | ﹤0.01% |
+4,193
| New | +$14.2K |
|
|
THRD
546
DELISTED
Third Harmonic Bio
THRD
| $9.73K | ﹤0.01% |
+946
| New | +$11.8K |
|
547
Theravance Biopharma
TBPH
$873M
| $9.72K | ﹤0.01% |
+1,033
| New | +$9.4K |
|
|
CHCT
548
Community Healthcare Trust
CHCT
$536M
| $9.72K | ﹤0.01% |
+506
| New | +$9.17K |
|
|
FPI
549
Farmland Partners
FPI
$415M
| $9.7K | ﹤0.01% |
+825
| New | +$9.68K |
|
550
Arcturus Therapeutics
ARCT
$165M
| $9.66K | ﹤0.01% |
+569
| New | +$10.7K |
|
Similar funds
CM
BP
AAM
CAG
WHRC
RCG
AL
CGPCS
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.